Holen Sie sich die Stockscreener-App
1.53
0.00%
0.00
Handel nachbörslich:
1.52
-0.01
-0.65%
Schlusskurs vom Vortag:
$1.53
Offen:
$1.5392
24-Stunden-Volumen:
77,626
Relative Volume:
1.15
Marktkapitalisierung:
$40.25M
Einnahmen:
$9.06M
Nettoeinkommen (Verlust:
$-50.39M
KGV:
-0.7969
EPS:
-1.92
Netto-Cashflow:
$5.89M
1W Leistung:
+0.00%
1M Leistung:
+12.50%
6M Leistung:
+64.16%
1J Leistung:
-15.00%
1-Tages-Spanne:
$1.52
$1.55
1-Wochen-Bereich:
$1.51
$1.56
52-Wochen-Spanne:
$0.8502
$2.093
Lava Therapeutics Nv Stock (LVTX) Company Profile
Firmenname
Lava Therapeutics Nv
Sektor
Branche
Telefon
31 6 3000 3035
Adresse
YALELAAN 62, UTRECHT
Vergleichen Sie LVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LVTX
Lava Therapeutics Nv
|
1.53 | 39.98M | 9.06M | -50.39M | 5.89M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Lava Therapeutics Nv Stock (LVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-12 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-12-11 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-04-19 | Eingeleitet | Jefferies | Buy |
| 2021-04-19 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Lava Therapeutics Nv Aktie (LVTX) Neueste Nachrichten
LAVA Reports Second Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
LAVA Therapeutics Agrees to XOMA Buyout Deal as Cancer Drug Development Halts - Stock Titan
Published on: 2025-08-13 07:23:25 - Newser
Automated trading signals detected on LAVA Therapeutics N.V.Quarterly Trade Summary & AI Powered Market Entry Ideas - Newser
Published on: 2025-08-13 04:30:20 - Newser
Real time scanner hits for LAVA Therapeutics N.V. explainedMarket Volume Report & Free Community Consensus Stock Picks - Newser
Real time breakdown of LAVA Therapeutics N.V. stock performanceJuly 2025 Market Mood & High Yield Equity Trading Tips - Newser
Is a relief rally coming for LAVA Therapeutics N.V. holdersBuy Point Strategy with Profit Protection - Newser
Has LAVA Therapeutics N.V. formed a bullish divergence2025 Institutional Moves & Long Hold Capital Preservation Plans - Newser
LAVA Therapeutics N.V. stock momentum explainedDay Trading Plan with Entry Risk Management - Newser
What earnings revisions data tells us about LAVA Therapeutics N.V.Free Secure Capital Picks With Upside Potential - Newser
Is it too late to sell LAVA Therapeutics N.V.Free Beginner Friendly Stock Selection Guide - Newser
What makes LAVA Therapeutics N.V. stock price move sharplyTrade Plan With Low Risk High Return - Newser
Signal strength of LAVA Therapeutics N.V. stock in tech scannersFree Low Risk Picks for Daily Trading - Newser
Tools to assess LAVA Therapeutics N.V.’s risk profileImmediate Entry Point Prediction Strategy - Newser
Is LAVA Therapeutics N.V. stock poised for growthFree Multi-Bagger Potential Stock Forecast Tools - Newser
How LAVA Therapeutics N.V. stock performs during market volatilityPattern Breakout Tracker with Screener Tools - Newser
LAVA Therapeutics N.V.’s Price Action Aligns with Quant SignalsEntry Zone Strategy for Consistent Profit Shared - metal.it
Can a trend reversal in LAVA Therapeutics N.V. lead to recoveryFree Risk-Adjusted Picks With Exit Strategy - Newser
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of LAVA Therapeutics N.V. (NASDAQ: LVTX) - Eastern Progress
XOMA Royalty Announces Dual Acquisitions of HilleVax and LAVA Therapeutics - MSN
Will breakout in LAVA Therapeutics N.V. lead to full recoveryRisk Managed Watchlist with Breakout Picks - Newser
Lava Therapeutics shares rise 1.18% intraday after XOMA Royalty Corporation acquisition announcement. - AInvest
LAVA Therapeutics (NASDAQ:LVTX) Cut to “Hold” at Jefferies Financial Group - Defense World
Investigation into Steelcase, LAVA Therapeutics, and Enzo Biochem on Behalf of Shareholders - AInvest
Live market analysis of LAVA Therapeutics N.V.Stock Forecast Tools for Retail Traders - Newser
East Bay’s Xoma adds two more biotechs to its portfolio - The Business Journals
This Block Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Jefferies downgrades Lava Therapeutics stock to Hold on XOMA acquisition By Investing.com - Investing.com Australia
Finanzdaten der Lava Therapeutics Nv-Aktie (LVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):